Search research articles
Contact Us
Filters
Showing results (1291-1300 of 1,320) with videos related to
Page
of 132
Sort By:
Plos One
|
October 18, 2011
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults
Martha Sedegah, Cindy Tamminga, Shannon McGrath, et al.
Science (New York, N.Y.)
|
September 10, 2011
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity
J E Epstein, K Tewari, K E Lyke, et al.
Lancet (London, England)
|
January 18, 2011
Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies
Muredach P Reilly, Mingyao Li, Jing He, et al.
Plos One
|
October 18, 2011
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component
Cindy Tamminga, Martha Sedegah, David Regis, et al.
Circulation. Cardiovascular Genetics
|
October 7, 2010
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls
Michael Preuss, Inke R König, John R Thompson, et al.
Plos One
|
September 8, 2021
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
Marvin J Sklar, Santina Maiolatesi, Noelle Patterson, et al.
Human Vaccines & Immunotherapeutics
|
November 16, 2012
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA
Thomas L Richie, Yupin Charoenvit, Ruobing Wang, et al.
Plos One
|
March 5, 2013
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity
Ilin Chuang, Martha Sedegah, Susan Cicatelli, et al.
JCI Insight
|
January 19, 2017
Protection against <i>Plasmodium falciparum</i> malaria by PfSPZ Vaccine
Judith E Epstein, Kristopher M Paolino, Thomas L Richie, et al.
Science (New York, N.Y.)
|
August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine
Robert A Seder, Lee-Jah Chang, Mary E Enama, et al.
Page
of 132
Search research articles
Search
Showing results (1291-1300 of 1,320) with videos related to
Sort By:
Page
of 132
Plos One
|
October 18, 2011
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults
Martha Sedegah, Cindy Tamminga, Shannon McGrath, et al.
Science (New York, N.Y.)
|
September 10, 2011
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity
J E Epstein, K Tewari, K E Lyke, et al.
Lancet (London, England)
|
January 18, 2011
Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies
Muredach P Reilly, Mingyao Li, Jing He, et al.
Plos One
|
October 18, 2011
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component
Cindy Tamminga, Martha Sedegah, David Regis, et al.
Circulation. Cardiovascular Genetics
|
October 7, 2010
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls
Michael Preuss, Inke R König, John R Thompson, et al.
Plos One
|
September 8, 2021
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
Marvin J Sklar, Santina Maiolatesi, Noelle Patterson, et al.
Human Vaccines & Immunotherapeutics
|
November 16, 2012
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA
Thomas L Richie, Yupin Charoenvit, Ruobing Wang, et al.
Plos One
|
March 5, 2013
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity
Ilin Chuang, Martha Sedegah, Susan Cicatelli, et al.
JCI Insight
|
January 19, 2017
Protection against <i>Plasmodium falciparum</i> malaria by PfSPZ Vaccine
Judith E Epstein, Kristopher M Paolino, Thomas L Richie, et al.
Science (New York, N.Y.)
|
August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine
Robert A Seder, Lee-Jah Chang, Mary E Enama, et al.
Page
of 132